OMERS ADMINISTRATION Corp Invests $152,000 in uniQure N.V. $QURE

Key Points

• OMERS ADMINISTRATION Corp has invested approximately $152,000 in uniQure N.V. by acquiring 14,300 shares of the biotechnology company in the first quarter.
• Insider selling activity includes Jeannette Potts selling 4,670 shares for a total of $70,703.80, which marks a 3.90% decrease in their holdings.
• Analysts are optimistic about uniQure, with brokerages setting target prices ranging from $28.00 to $70.00, resulting in a consensus rating of "Buy" for the stock.

OMERS ADMINISTRATION Corp bought a new position in shares of uniQure N.V. (NASDAQ:QURE - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 14,300 shares of the biotechnology company's stock, valued at approximately $152,000.

Several other large investors also recently made changes to their positions in the business. Mraz Amerine & Associates Inc. bought a new position in uniQure in the first quarter valued at about $106,000. Wells Fargo & Company MN increased its position in uniQure by 13.9% in the fourth quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company's stock worth $217,000 after purchasing an additional 1,503 shares during the period. XTX Topco Ltd increased its position in uniQure by 127.3% in the first quarter. XTX Topco Ltd now owns 36,999 shares of the biotechnology company's stock worth $392,000 after purchasing an additional 20,720 shares during the period. Lighthouse Investment Partners LLC acquired a new stake in uniQure in the fourth quarter worth about $397,000. Finally, Tudor Investment Corp ET AL boosted its holdings in uniQure by 5.9% during the fourth quarter. Tudor Investment Corp ET AL now owns 24,784 shares of the biotechnology company's stock worth $438,000 after buying an additional 1,371 shares during the last quarter. Institutional investors own 78.83% of the company's stock.

Insider Activity

In other uniQure news, insider Jeannette Potts sold 4,670 shares of the company's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $15.14, for a total transaction of $70,703.80. Following the completion of the transaction, the insider owned 115,073 shares of the company's stock, valued at $1,742,205.22. This represents a 3.90% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Rachelle Suzanne Jacques sold 2,112 shares of the company's stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $14.45, for a total value of $30,518.40. Following the transaction, the director directly owned 28,346 shares of the company's stock, valued at approximately $409,599.70. This trade represents a 6.93% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 22,144 shares of company stock worth $322,426. 4.79% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of brokerages have issued reports on QURE. Guggenheim restated a "buy" rating and set a $28.00 target price on shares of uniQure in a report on Monday, May 12th. HC Wainwright restated a "buy" rating and set a $70.00 target price on shares of uniQure in a report on Thursday, May 29th. Cantor Fitzgerald set a $47.00 target price on uniQure in a report on Wednesday, July 30th. Mizuho upgraded uniQure from a "neutral" rating to an "outperform" rating and set a $30.00 target price on the stock in a report on Thursday, August 14th. Finally, Wall Street Zen upgraded uniQure from a "sell" rating to a "hold" rating in a report on Saturday, August 2nd. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $37.45.

uniQure Trading Up 2.0%

NASDAQ:QURE opened at $17.73 on Friday. uniQure N.V. has a twelve month low of $4.45 and a twelve month high of $19.18. The company has a quick ratio of 9.98, a current ratio of 9.98 and a debt-to-equity ratio of 1.53. The business has a 50 day moving average price of $14.90 and a two-hundred day moving average price of $13.77. The company has a market cap of $972.85 million, a P/E ratio of -4.52 and a beta of 0.14.

uniQure (NASDAQ:QURE - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share for the quarter, topping analysts' consensus estimates of ($0.89) by $0.20. uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%.The firm had revenue of $5.26 million during the quarter, compared to the consensus estimate of $5.00 million. As a group, analysts expect that uniQure N.V. will post -3.75 EPS for the current fiscal year.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.